

# AvMed

## PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST\*

**Directions:** The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; **fax to 1-305-671-0200.** No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

### **Drug Requested** (select one below):

<input type="checkbox"/> <b>candesartan</b> (Atacand <sup>®</sup> )	<input type="checkbox"/> <b>candesartan-HCTZ</b> (Atacand HCT <sup>®</sup> )
<input type="checkbox"/> <b>Edarbi</b> <sup>®</sup> (azilsartan)	<input type="checkbox"/> <b>Edarbyclor</b> <sup>®</sup> (azilsartan & chlorthalidone)
<input type="checkbox"/> <b>aliskiren</b> (Tekturna <sup>®</sup> )	<input type="checkbox"/> <b>Tekturna HCT</b> <sup>®</sup> (aliskiren & hydrochlorothiazide)

### **MEMBER & PRESCRIBER INFORMATION:** Authorization may be delayed if incomplete.

Member Name: \_\_\_\_\_

Member AvMed #: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Prescriber Name: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Office Contact Name: \_\_\_\_\_

Phone Number: \_\_\_\_\_ Fax Number: \_\_\_\_\_

DEA OR NPI #: \_\_\_\_\_

### **DRUG INFORMATION:** Authorization may be delayed if incomplete.

Drug Form/Strength: \_\_\_\_\_

Dosing Schedule: \_\_\_\_\_ Length of Therapy: \_\_\_\_\_

Diagnosis: \_\_\_\_\_ ICD Code, if applicable: \_\_\_\_\_

Weight: \_\_\_\_\_ Date: \_\_\_\_\_

**CLINICAL CRITERIA:** Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

(Continued on next page)

**For candesartan/HCTZ, Edarbi® and Edarbyclor® requests:**

- Member has tried and failed 30 days of therapy with **at least one (1)** of the following (verified by chart notes or pharmacy paid claims):

<input type="checkbox"/> amlodipine-olmesartan	<input type="checkbox"/> losartan	<input type="checkbox"/> telmisartan
<input type="checkbox"/> amlodipine-valsartan	<input type="checkbox"/> losartan-HCTZ	<input type="checkbox"/> valsartan
<input type="checkbox"/> irbesartan	<input type="checkbox"/> olmesartan	<input type="checkbox"/> valsartan-HCTZ
<input type="checkbox"/> irbesartan-HCTZ	<input type="checkbox"/> olmesartan-HCTZ	

**For aliskiren (Tekturna®) or Tekturna HCT® requests:**

- Member has tried and failed 30 days of therapy with **at least one (1)** of the following (verified by chart notes or pharmacy paid claims):

<input type="checkbox"/> amlodipine-olmesartan	<input type="checkbox"/> losartan	<input type="checkbox"/> telmisartan
<input type="checkbox"/> amlodipine-valsartan	<input type="checkbox"/> losartan-HCTZ	<input type="checkbox"/> valsartan
<input type="checkbox"/> irbesartan	<input type="checkbox"/> olmesartan	<input type="checkbox"/> valsartan-HCTZ
<input type="checkbox"/> irbesartan-HCTZ	<input type="checkbox"/> olmesartan-HCTZ	

**AND**

- Member has tried and failed 30 days of therapy with Edarbi® or Edarbyclor®

**If requesting candesartan tablets for migraine prevention:**

- Provider must submit documentation to confirm indication for use

*Not all drugs may be covered under every Plan.*

*If a drug is non-formulary on a Plan, documentation of medical necessity will be required.*

*\*\*Use of samples to initiate therapy does not meet step edit/preauthorization criteria.\*\**

*\*Previous therapies will be verified through pharmacy paid claims or submitted chart notes.\**

\*Approved by Pharmacy and Therapeutics Committee on: 11/19/2012; 5/23/2024

REVISED/UPDATED/REFORMATTED: 1/19/2016; 12/16/2016; 8/12/2017; 6/10/2019; 1/6/2022; 4/25/2022; 6/15/2022; 6/16/2022; 5/17/2024; 6/5/2024